Scott Checketts, MD
Dermatology · Layton, UTNPI 1790762961
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,143 of the $2,398 with a category attached, or 89.4%. 26 manufacturers reported payments, led by AbbVie at 33.9% of the total. Reporting peaked in 2024 at $659 and has fallen 71.7% since, to $187 in 2025.
Across 171 payments — averaging $14.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$812
- Novartis$372
- Johnson & Johnson$322
- Sun Pharmaceutical Industries Inc.$106
- Arcutis Biotherapeutics, Inc.$71
- Dermavant Sciences, Inc.$71
- plus $644 from 20 others
Across 52 payments — averaging $4316.43 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi US Services Inc.$186K
- Eli Lilly$22K
- VYNE Pharmaceuticals Inc.$17K
What the payments were for
- Food & beverage$2,14389%
- Education$25511%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 86 | $812 |
| Novartis | 24 | $372 |
| Johnson & Johnson | 7 | $322 |
| Sun Pharmaceutical Industries Inc. | 5 | $106 |
| Arcutis Biotherapeutics, Inc. | 4 | $71 |
| Dermavant Sciences, Inc. | 4 | $71 |
| Galderma Laboratories, L.p. | 4 | $62 |
| Amgen | 3 | $56 |
| Lilly USA, LLC | 3 | $55 |
| LEO Pharma Inc. | 2 | $54 |
| Eisai Inc. | 4 | $53 |
| Actelion Pharmaceuticals US, Inc. | 1 | $44 |
| Prugen, Inc. Pharmaceuticals | 4 | $38 |
| E.r. Squibb & Sons, L.L.C. | 2 | $35 |
| Pfizer | 2 | $27 |
| Organon | 6 | $27 |
| Abbott | 1 | $24 |
| Dexcom, Inc. | 1 | $24 |
| Almirall LLC | 1 | $24 |
| Supernus Pharmaceuticals, Inc. | 1 | $22 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $20 |
| Biofrontera Inc. | 1 | $20 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 1 | $16 |
| UCB, Inc. | 1 | $16 |
| AstraZeneca | 1 | $15 |
| Incyte Corporation | 1 | $14 |
How this compares
$2,398 in reported general payments places this provider in the 60th percentile of 163 dermatology providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Clobetasol Propionate | 96 | $5,652 |
| Cyclosporine ModifiedCyclosporine, Modified | 15 | $3,454 |
| Minocycline Hcl | 25 | $1,839 |
| Ketoconazole | 35 | $936 |
| Triamcinolone Acetonide | 61 | $613 |
| Doxycycline Hyclate | 13 | $436 |
| Finasteride | 64 | $256 |
| Terbinafine Hcl | 21 | $197 |
| Mupirocin | 12 | $155 |
| Prednisone | 22 | $130 |
| Cephalexin | 18 | $99 |
| MethotrexateMethotrexate Sodium | 11 | $88 |
| Fluconazole | 12 | $53 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Layton
- Steven NickleLayton$11K
- Matthew InnesLayton$6K
- Jamison HarveyLayton$5K
- Michael MartineauLayton$3K
- Bradley NeuenschwanderLayton$3K
- Brayden ForbesLayton$2K
- Brian WilliamsMidvale$876K
- Travis JamesProvidence$437K
- Jason HadleyBountiful$294K
- Doug Lass ForshaWest Jordan$213K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.